Q1 2021 Agios Pharmaceuticals Inc Earnings Conference Call Read more about Q1 2021 Agios Pharmaceuticals Inc Earnings Conference Call
Agios Announces Closing of Oncology Business Sale to Servier Read more about Agios Announces Closing of Oncology Business Sale to Servier
Agios Shareholders Approve Sale of Oncology Business to Servier Read more about Agios Shareholders Approve Sale of Oncology Business to Servier
Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease Read more about Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease
Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma Read more about Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias Read more about Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias
Agios Reports Fourth Quarter and Full Year 2020 Financial Results Read more about Agios Reports Fourth Quarter and Full Year 2020 Financial Results
Agios to Present at March Investor Conferences Read more about Agios to Present at March Investor Conferences
Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021 Read more about Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021
Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused Read more about Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused